Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZE63-0302 in Type 2 Diabetes Mellitus
NCT07234864Phase 1Active, not recruiting
- Sponsor
- Eilean Therapeutics
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ZE63-0302 treatment with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 4 weeks, Change from baseline in vital signs and physical examination findings at 4 weeks and 2 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
balamenib
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07234864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234864.